跳至主要内容
临床试验/JPRN-UMIN000014422
JPRN-UMIN000014422已完成未知

Prospective and randomized study on the efficacy of novel hypoglycemic type 2 diabetes agent ipragliflozin to serum glycemic control and cardiovascular risk factors - Prospective and randomized study on the efficacy of novel hypoglycemic type 2 diabetes agent ipragliflozin to serum glycemic control and cardiovascular risk factors

Fukui-ken Saiseikai Hospital0 个研究点目标入组 100 人开始时间: 2014年6月30日最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 65years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) With receiving insulin therapy 2) With a history of ischemic heart disease (angina pectoris, myocardial infarction) and ischemic stroke 3) Serum Creatinine >= 1.2 mg/dL 4) Fasting serum triglycerides levels >= 400 mg/dL 5) HbA1c was changed 2% or more within 3 months 6) With unconscious thirst (impossible self-judgement water intake) 7) With contraindication for ipragliflozin a) History of hypersensitivity to ipragliflozin b) Severe ketosis, diabetic or precoma c) Severe infection, pre or post surgery, and severe trauma 8) Considered as inadequate by the investigator

研究者

相似试验

Prospective and randomized study on the efficacy of... | 临床试验